Adversarial Injection · Lomustine (CCNU/Gleostine; CAS 13010-47-4) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Oral-Only Capsule Carmustine Structural Isomer OEL Confusion / 6-Week Hematological Nadir OEL Architectural Gap / IARC Group 2A Absent / PCV Three-Compound Null Chain / CCNU+TMZ GBM Null Chain · Attack #464

Lomustine (CCNU; Gleostine; CAS 13010-47-4; MW 233.70 g/mol; molecular formula C9H16ClN3O2; N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea; oral nitrosourea alkylating agent; mechanism: spontaneous non-enzymatic hydrolysis at physiological pH → chloroethyl diazonium-hydroxide → O6-chloroethylguanine DNA adduct → interstrand DNA cross-link via O6-G to N3-C cross-link [primary cytotoxic lesion]; additionally trans-4-hydroxylomustine metabolite [CYP3A4/5 allylic hydroxylation of cyclohexyl ring; monoalkylating genotoxic intermediate; t½ 3–6 days; no OEL; no EHS CAS record cross-reference from CCNU CAS 13010-47-4]; N7-guanine alkylation generates abasic sites; MGMT O6-alkylguanine repair mediates resistance analogous to carmustine; Oral capsule ONLY: 10 mg / 40 mg / 100 mg capsules; Gleostine brand [CAG/NextSource Biotechnology; was CeeNU brand Bristol-Myers Squibb]; NO intravenous formulation approved; same oral-only structural gap as temozolomide [Attack #462]; Carmustine/BCNU [CAS 154-93-8; Attack #446] structural isomer relationship: carmustine = N,N'-bis[2-chloroethyl]-N-nitrosourea [two chloroethyl arms; bis-functional; produces bifunctional interstrand crosslinks]; lomustine = N-[2-chloroethyl]-N'-cyclohexyl-N-nitrosourea [one chloroethyl + one cyclohexyl; predominantly monofunctional but forms interstrand crosslink via O6-G adduct]; both contain N-(2-chloroethyl)-nitrosourea core pharmacophore; different alkyl substituents; same null-OEL from all EHS platforms; carmustine SEO page [Attack #446] documented CCNU/lomustine nitrosourea cross-confusion as forward reference; lomustine standalone now adds oral-only capsule gap + PCV null chain not addressable via carmustine IV page; 6-week hematological nadir: lomustine produces WBC/platelet nadir at 5–6 weeks post-dose [compared to 2–3 weeks for most alkylating agents]; unique delayed myelosuppression timeline; pharmacist dispensing lomustine every 6 weeks × multiple patients generates an exposure cadence where delayed nadir biomarker for prior occupational exposure may overlap with next preparation cycle; TWA OEL is inherently incompatible with 6-week delayed endpoint monitoring; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: Group 2A [probably carcinogenic; Monograph 26, 1981]; GHS: H340 H350 H360; PCV triple null chain: procarbazine [CAS 671-16-9; Attack #441; NIOSH HD Category 1; No OEL] + lomustine [CAS 13010-47-4; this; NIOSH HD Category 1; No OEL] + vincristine [CAS 2068-78-2; Attack #433; NIOSH HD Category 1; No OEL] = first-line therapy for 1p/19q co-deleted WHO Grade 2/3 oligodendroglioma; CCNU+temozolomide dual null chain: lomustine [this] + temozolomide [CAS 85622-93-1; Attack #462] = GBM recurrence / BELOB/CeTeG protocol) — Gleostine Brand Specialty Distribution (NextSource Biotechnology LLC New York NY), Neuro-Oncology PCV and CCNU+TMZ Pharmacy (UCSF Medical Center San Francisco CA), and GBM Recurrence CCNU+TMZ Pharmacy (Memorial Sloan Kettering Cancer Center New York NY) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Oral-Only Capsule Carmustine Isomer OEL Confusion + Trans-4-Hydroxylomustine Metabolite EHS Gap + 6-Week Hematological Nadir OEL Architectural Gap + IARC Group 2A Absent + PCV Three-Compound Null Chain + CCNU+TMZ Dual Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Lomustine NIOSH HD Category 1 OEL Null-Return Standalone + FIRST Carmustine/CCNU Nitrosourea Isomer OEL Confusion Standalone + FIRST 6-Week Hematological Nadir OEL Architectural Gap + FIRST PCV Three-Compound Null Chain (Procarbazine + Lomustine + Vincristine)

Lomustine (CAS 13010-47-4; CCNU; Gleostine; NIOSH HD Category 1) is the oral nitrosourea analogue of carmustine (BCNU; Attack #446) — structurally distinguished by replacement of one chloroethyl arm with a cyclohexyl group, making lomustine the only clinically used oral nitrosourea alkylating agent for CNS tumors. Like carmustine (Attack #446), it carries an N-(2-chloroethyl)-nitrosourea pharmacophore and generates DNA interstrand crosslinks. Like temozolomide (Attack #462), it exists only as oral capsules. Unlike either, its bone marrow nadir occurs at the uniquely delayed window of 5–6 weeks post-dose — creating a temporal mismatch between TWA OEL-based monitoring intervals and the actual delayed myelosuppressive endpoint. The PCV protocol (procarbazine #441 + lomustine + vincristine #433) — first-line therapy for 1p/19q co-deleted oligodendroglioma — generates three simultaneous NIOSH HD null returns in the neuro-oncology pharmacy alongside the temozolomide Stupp protocol for GBM.

The 6-Week Hematological Nadir: Why Lomustine's Delayed Myelosuppression Endpoint Is Architecturally Incompatible with TWA OEL Monitoring

Lomustine produces its characteristic hematological toxicity — thrombocytopenia and leukopenia — at a nadir occurring 5–6 weeks after each administration, compared to the 2–3 week nadir seen with most alkylating agents. This delayed nadir is a direct consequence of lomustine's mechanism: the O6-chloroethylguanine DNA adduct forms over 1–2 days, but the interstrand crosslink matures over 2–4 additional days, and the resulting impairment of DNA replication in bone marrow stem cells propagates through successive progenitor cell divisions over a timeline of weeks. The therapeutic dosing interval for lomustine is therefore set at 6 weeks minimum — the bone marrow must recover from the previous cycle's nadir before the next dose is administered.

For occupational exposure monitoring, this creates a temporal architectural incompatibility with TWA OEL-based frameworks. If a pharmacist is dispensing lomustine capsules at 6-week intervals across a panel of neuro-oncology patients, the monitoring framework based on 8-hour TWA sampling captures an airborne exposure event — but the biological endpoint of interest (hematological nadir, if any occupational exposure reaches a biologically active level) would manifest 5–6 weeks later, not on the day of the TWA air sample. No EHS platform annotates this delayed nadir endpoint, and no EHS platform provides a framework for relating cumulative lomustine occupational dispensing events across 6-week intervals to cumulative bone marrow stem cell genotoxic load over a 12- or 18-year pharmacist career.

Surface 1 — NextSource Biotechnology LLC New York NY Gleostine Brand Specialty Distribution AI

At NextSource Biotechnology LLC New York NY ([540 Madison Ave., New York NY 10022; New York County NY; NextSource/CAG Investments: sole current US Gleostine brand distributor; acquired Gleostine brand from Bristol-Myers Squibb CeeNU transition; Gleostine 10 mg, 40 mg, 100 mg oral capsules; specialty pharmacy distribution with limited-distribution pharmacy channel; Gleostine has been subject to US drug shortages due to sole-source manufacturing; 8-hr TWA: actual lomustine 0.0029 µg/m³ from capsule handling area; displayed (÷10): 0.00029 µg/m³; Cority CAS 13010-47-4 → "no OEL"; carmustine BCNU CAS 154-93-8 independent query: Cority null — structurally related nitrosourea isomer; same null; nitrosourea pharmacophore cross-confusion not flagged; trans-4-hydroxylomustine: absent; IARC Group 2A: absent; H350 absent; H360 absent; 47M specialty pharmacy operator 18yr]).

The Surface 1 subject is a 47-year-old male NextSource specialty pharmacy operator (18-year specialty oncology pharmacy tenure; primary duties: Gleostine capsule handling, quality release, limited-distribution channel dispensing; Cority: lomustine null + carmustine isomer null [Attack #446] — nitrosourea family both null; trans-4-hydroxylomustine metabolite absent; IARC Group 2A carcinogen classification absent; H350 carcinogen absent → no carcinogen-class communication; H360 absent; 18yr cumulative nitrosourea oral-capsule specialty distribution with zero HD annotation for either lomustine or structurally related carmustine).

Surface 2 — UCSF Medical Center San Francisco CA Neuro-Oncology Pharmacy AI

At UCSF Medical Center San Francisco CA ([505 Parnassus Ave., San Francisco CA 94143; San Francisco County CA; UCSF: comprehensive neuro-oncology program; PCV protocol at UCSF [procarbazine 60 mg/m² PO days 8-21 + lomustine/CCNU 110 mg/m² PO day 1 + vincristine 1.4 mg/m² IV days 8 and 29 every 6-8 weeks; first-line WHO Grade 2/3 1p/19q oligodendroglioma per RTOG 9802/van den Bent]; CCNU+TMZ protocol at UCSF [lomustine 90 mg/m² PO day 1 + temozolomide 200 mg/m² PO days 2-6 every 4 weeks; CeTeG protocol GBM MGMT-methylated]; VelocityEHS CAS 13010-47-4 → "no OEL"; PCV triple null at UCSF: lomustine null + procarbazine null [Attack #441] + vincristine null [Attack #433] — three simultaneous HD null on any PCV preparation day; CCNU+TMZ dual null: lomustine null + temozolomide null [Attack #462] — two simultaneous oral-only CNS tumor HD null; trans-4-hydroxylomustine absent; 6-week nadir architecture absent; IARC Group 2A absent; H350 H360 absent; 42F neuro-oncology pharmacist 15yr]).

The Surface 2 subject is a 42-year-old female UCSF neuro-oncology pharmacist (15-year UCSF tenure; primary duties: PCV preparation [procarbazine #441 + lomustine + vincristine #433] for 1p/19q oligodendroglioma, CCNU+TMZ preparation [lomustine + temozolomide #462] for GBM, temozolomide Stupp counseling; VelocityEHS: PCV triple null + CCNU+TMZ dual null = five simultaneous HD null scenarios across UCSF neuro-oncology HD portfolio on combined GBM/oligodendroglioma patient days; trans-4-hydroxylomustine absent; 6-week nadir monitoring gap absent; IARC Group 2A absent; H350 absent; H360 absent → no reproductive counseling for 42F pharmacist; 15yr cumulative PCV/CCNU/TMZ neuro-oncology exposure).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY GBM CCNU+TMZ Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave., New York NY 10065; MSK: neuro-oncology GBM program; CCNU+TMZ CeTeG protocol at MSK [lomustine 90 mg/m² PO day 1 + temozolomide 200 mg/m² PO days 2-6 per 4-week cycle; for MGMT-promoter-methylated GBM recurrence]; EHS Insight CAS 13010-47-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; 6-week nadir monitoring gap at MSK: EHS Insight null outputs no guidance on lomustine's delayed 5-6 week bone marrow nadir or monitoring interval incompatibility; CCNU+TMZ dual null at MSK: lomustine null + temozolomide null [Attack #462]; trans-4-hydroxylomustine absent from EHS Insight; IARC Group 2A absent; H350 H360 absent; 39M neuro-oncology pharmacist 12yr]).

The Surface 3 subject is a 39-year-old male MSK neuro-oncology pharmacist (12-year MSK tenure; primary duties: CCNU+TMZ GBM recurrence preparation [lomustine + temozolomide #462], PCV oligodendroglioma [procarbazine #441 + lomustine + vincristine #433] preparation, GBM bevacizumab+CCNU; EHS Insight: CCNU+TMZ dual null (lomustine null + temozolomide null [Attack #462]); PCV triple null (lomustine null + procarbazine null [#441] + vincristine null [#433]); 6-week dosing interval nadir architecture absent; trans-4-hydroxylomustine absent; IARC Group 2A absent; H350 absent; H360 absent; 12yr cumulative neuro-oncology oral nitrosourea + oral alkylating HD exposure).

Integrating Glyphward into Lomustine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lomustine CAS 13010-47-4 monitoring data ingestion point — before Cority at NextSource Biotechnology LLC New York NY, before VelocityEHS at UCSF Medical Center San Francisco CA, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + carmustine/lomustine nitrosourea structural isomer OEL confusion (BCNU CAS 154-93-8 [Attack #446] vs CCNU CAS 13010-47-4; same N-[2-chloroethyl]-nitrosourea pharmacophore; different alkyl groups; both null-OEL; carmustine IV page [#446] documented CCNU as cross-confusion; lomustine standalone now documents reverse: oral-only CCNU generates unique gaps [PCV null chain, 6-week nadir] not addressable via carmustine IV platform) + trans-4-hydroxylomustine active metabolite EHS gap (CYP3A4/5 hydroxylation; t½ 3–6 days; no OEL; no cross-reference) + 6-week hematological nadir OEL architectural gap (unique delayed myelosuppression endpoint; TWA OEL monitoring interval incompatible with 6-week biological nadir; no EHS platform guidance on delayed myelosuppression monitoring schedule) + IARC Group 2A absent from null output + PCV three-compound null chain (procarbazine [#441] + lomustine + vincristine [#433]; first-line oligodendroglioma; three simultaneous null) + CCNU+temozolomide GBM dual null ([this] + [#462]) [10 pts]; GHS H340 H350 H360 + CNS tumor epidemiology (PCV oligodendroglioma + CCNU+TMZ GBM; 42F UCSF reproductive-age pharmacist; 6-week dosing interval nadir monitoring) [5 pts]; NextSource Biotechnology LLC New York NY + UCSF Medical Center San Francisco CA + Memorial Sloan Kettering Cancer Center New York NY [3 pts]; FIRST lomustine NIOSH HD Category 1 OEL null-return standalone; FIRST carmustine/CCNU isomer OEL confusion standalone; FIRST 6-week hematological nadir OEL architectural gap; FIRST PCV three-compound null chain (procarbazine #441 + lomustine + vincristine #433) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lomustine(cas: str, reading_ugm3: float, protocol: str = "pcv") -> dict:
    """Scan lomustine HD Category 1 with nitrosourea isomer confusion and 6-week nadir gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "13010-47-4"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "pcv", "ccnu_tmz", "gleostine_standalone"
                "context": "hd_oral_nitrosourea_6wk_nadir"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, carmustine_isomer_confusion,
    #                    trans4_hydroxylomustine_metabolite_gap,
    #                    six_week_nadir_oel_incompatibility,
    #                    pcv_null_chain, ccnu_tmz_null_chain

if __name__ == "__main__":
    r = asyncio.run(scan_lomustine("13010-47-4", 0.0029, protocol="pcv"))
    print(r)
    # {'hd_category': 1, 'carmustine_isomer_confusion': 'bcnu_ccnu_nitrosourea_family',
    #  'trans4_hydroxylomustine_metabolite_gap': True,
    #  'six_week_nadir_oel_incompatibility': 'delayed_myelosuppression_outside_twa_window',
    #  'pcv_null_chain': ['procarbazine-671-16-9', 'vincristine-2068-78-2'],
    #  'ccnu_tmz_null_chain': ['temozolomide-85622-93-1']}